Compare ARMOUR Residential REIT, Inc. (ARR) vs Invesco Ltd. (IVZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs Invesco Ltd. — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.66 (market cap $2.07B), while Invesco Ltd. trades at $31.53 (market cap $13.85B). The key difference: Invesco Ltd. is far larger — about 6.7× ARMOUR Residential REIT, Inc.'s market cap, and ARMOUR Residential REIT, Inc. pays the higher dividend (17.28%). Which is the better fit depends on your goals.
| ARR | IVZ | |
|---|---|---|
Market Cap | $2.07B | $13.85B |
Sector | Financials | Financials |
52-Week High | $19.12 | $32.01 |
52-Week Low | $14.05 | $20.67 |
Dividend Yield | 17.28% | 2.74% |
Enterprise Value | — | $24.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARR trades at $16.67, up 0.79% today, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a net income margin of 97.43% and a low P/E of 3.78, but revenue volatility and high investing cash outflows pose concerns. Recent dividends of $0.24 per share highlight income appeal, while analyst consensus is predominantly hold.
Outlook is cautious due to inconsistent EPS performance and significant cash flow swings, though valuation metrics suggest potential undervaluation. Risks include earnings misses and macroeconomic sensitivity, but the high dividend yield and low P/B ratio offer value for income-focused investors amid neutral market sentiment.
Invesco (IVZ) trades at $31.58, down 0.5% today but near its 52-week high, with a bullish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue has grown to $6.38 billion in 2025, though net income remains negative. Analyst consensus is a $32.50 price target with a mix of Buy and Hold ratings, and the firm maintains a stable dividend payout.
The outlook for IVZ is cautiously optimistic, supported by strong assets under management and positive cash flow trends. However, profitability challenges and expense pressures pose risks. Upside potential hinges on earnings improvement and market sentiment, while downside risks include margin compression and competitive pressures in asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About Invesco Ltd.
Invesco provides investment-management services to retail (65% of managed assets) and institutional (35%) clients. At the end of August 2022, the firm had $1.416 trillion in assets under management spread among its equity (47% of AUM), balanced (5%), fixed-income (22%), alternative investment (14%), and money market (12%) operations. Passive products account for 32% of Invesco's total AUM, including 56% of the company's equity operations and 13% of its fixed-income platform. Invesco's U.S. retail business is one of the 10 largest nonproprietary fund complexes in the country. The firm also has a meaningful presence outside the U.S., with close to one third of its AUM sourced from Canada (2%), the U.K. (4%), continental Europe (11%), and Asia (15%).
Read more on IVZ →
